Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897505 | 0.79 | NR1H2 (0.55) | NR1H2CA12CA9NR1H3 | |
| SCHEMBL30619487 | 0.78 | NR1H2 (0.64) | NR1H2CA12CA9NR1H3 | |
| SCHEMBL2872754 | 0.77 | ALDH1A1 (0.46) | — | |
| SCHEMBL5635574 | 0.77 | NR1H2 (0.67) | NR1H2CA12CA9NR1H3 | |
| SCHEMBL4565579 | 0.76 | NR1H2 (0.52) | NR1H2CA12CA9NR1H3 | |
| SCHEMBL17827647 | 0.75 | NR1H2 (0.47) | NR1H2CA12CA9NR1H3 | |
| SCHEMBL28578718 | 0.74 | NR1H2 (0.69) | NR1H2CA12CA9NR1H3 | |
| SCHEMBL9846756 | 0.74 | NR1H2 (0.48) | NR1H2CA12CA9NR1H3 | |
| SCHEMBL14367891 | 0.73 | NR1H2 (0.75) | NR1H2NR1H3 | |
| SCHEMBL21247054 | 0.73 | NR1H2 (0.64) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY11, P2RY1, P2RY13 | NR1H2 2560/4885CA12 3811/4885CA9 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.